AbbVie's Rinvoq Patent Win: A $6 Billion Boost
Update: 2025-09-11
Description
AbbVie's stock price surged after a patent settlement extended Rinvoq's exclusivity until 2037, beating expectations and sending shares to a 52-week high. The deal secures billions in revenue as Rinvoq offsets Humira losses, boosting investor confidence and solidifying AbbVie's position in the pharmaceutical market.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
